Long-Term Outcomes in Real Life of Lumacaftor–Ivacaftor Treatment in Adolescents With Cystic Fibrosis

Long-Term Outcomes in Real Life of Lumacaftor–Ivacaftor Treatment in Adolescents With Cystic Fibrosis

Background: The combination of the CFTR corrector lumacaftor (LUM) and potentiator ivacaftor (IVA) has been labeled in France since 2015 for F508del homozygote cystic fibrosis (CF) patients over 12 years. In this real-life study, we aimed (i) to compare the changes in lung function, clinical (e.g.,...

Full description

Saved in:
Bibliographic Details
Main Authors: Stéphanie Bui, Alexandra Masson, Raphaël Enaud, Léa Roditis, Gaël Dournes, François Galode, Cyrielle Collet, Emmanuel Mas, Jeanne Languepin, Michael Fayon, Fabien Beaufils, Marie Mittaine
Format: article
Language:EN
Published: Frontiers Media S.A. 2021
Subjects:
cystic fibrosis
child
CFTR potentiator
CFTR corrector
lung function testing
nutritional status
Pediatrics
RJ1-570
Online Access:https://doaj.org/article/cf2af5d930334a16a3f31dfa40ab41d4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/cf2af5d930334a16a3f31dfa40ab41d4

Similar Items